As previously reported, increased levels of soluble(s) CD163 at 6 weeks could predict the efficacy of nivolumab monotherapy 2–3 months after its first administration for the treatment of advanced cutaneous melanoma (24). Here, CD163 is linked to cutaneous melanoma.